Evaluating the effectiveness of influenza vaccine in kidney transplant recipients in Imam Khomeini Hospital

Phase 1

Completed

• Conditions: Other complication of kidney transplant; Kidney Transplant Recipients.; T86.19

• Registration Number: IRCT20210121050096N1
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 29 November 2021

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

At least 18 years old
At least three months have passed since their transplant.

Exclusion Criteria

Treatment for acute transplantation reject
Acute febrile illness in the last two weeks
Previous life-threatening reactions to vaccine products (such as Guillain-Barré syndrome)
Patients with any autoimmune disease receiving corticosteroids or immunosuppressive drugs.
Patients who have recently underwent kidney transplant.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Influenza A's Antibody. Timepoint: Before intervention and four weeks after vaccination. Method of measurement: Evaluating the influenzas' antibodies by serology.;Influenza B's Antibody. Timepoint: Before intervention and four weeks after vaccination. Method of measurement: Evaluating the influenzas' antibodies by serology.

Secondary Outcome Measures

Name	Time	Method
Fever. Timepoint: 3 days after injection. Method of measurement: Clinical Examination.;Getting the flu. Timepoint: 3 days after injection. Method of measurement: Evaluation of the patient's clinical symptoms.;Existence of pain at the injection site. Timepoint: 3 days after injection. Method of measurement: Clinical Examination.;Redness at the injection site. Timepoint: 3 days after injection. Method of measurement: Clinical Examination.;Systemic side effects. Timepoint: 3 days after injection. Method of measurement: Clinical Examination.